Hólyagrák: vizsgálatok itt: Kína
167 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Jiaxing, Nanchang, Nanjing, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Zhuhai
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07419295 · EU 2024-520014-22-00 - No phaseTaking peopleWhole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer
- Where
- Chongqing
- People
- 2000
- Run by
- Mingzhao Xiao
See details and how to joinNCT06389019 - 1. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00 - 1. fázisNot yet taking people in KínaDV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 20
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07853053 - 1. fázisTaking peopleFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Where
- Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi’an
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Beijing, Guangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 3. fázisTaking peopleA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai, Tianjin, Ürümqi, Wenzhou, Wuhan, Xinshi, Xuzhou
- Életkor
- 18 év and over
- People
- 641 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06319820 - 3. fázisTaking peopleA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Where
- Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan, Yantai
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00 - No phaseTaking peopleGuiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
- Where
- Guangzhou, Kunming, Nanchang, Shanghai, Tianjin, Xingtai
- Életkor
- 18 év and over
- People
- 350
- Run by
- Tianjin Medical University Second Hospital
See details and how to joinNCT07187635 - 2. fázisTaking peopleDisitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
- Where
- Taiyuan
- Életkor
- 18 év and over
- People
- 50
- Run by
- Shanxi Province Cancer Hospital
See details and how to joinNCT07646145 - 2. fázisTaking peopleA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
- Where
- Beijing, Chengdu, Langfang, Shanghai
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806 - 2. fázisNot yet taking people in KínaNeoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 20
- Run by
- Peking University First Hospital
See details and how to joinNCT07720921 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Chengdu, Guangzhou
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 2. fázisNot yet taking people in KínaAntibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
- Where
- Tianjin, Xingtai
- Életkor
- 18 év and over
- People
- 150
- Run by
- Tianjin Medical University Second Hospital
See details and how to joinNCT07879469 - No phaseTaking peopleUrinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 477
- Run by
- Ruijin Hospital
See details and how to joinNCT07888374 - 2. fázisTaking peopleIs Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
- Where
- Tianjin, Xingtai
- Életkor
- 18 év and over
- People
- 120
- Run by
- Tianjin Medical University Second Hospital
See details and how to joinNCT07625527 - No phaseTaking people18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 80
- Run by
- Peking University First Hospital
See details and how to joinNCT07875959 - No phaseTaking peopleComparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
- Where
- Guangzhou
- Életkor
- 18 év to 100 év
- People
- 96
- Run by
- Zhujiang Hospital
See details and how to joinNCT03108196 - 2. fázisTaking peopleNeoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 41
- Run by
- Zhujiang Hospital
See details and how to joinNCT04861584 - No phaseTaking peopleComparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men With Bladder Cancer
- Where
- Guangzhou
- Életkor
- 20 év and over
- People
- 126
- Run by
- Zhujiang Hospital
See details and how to joinNCT05067101 - No phaseTaking peopleActive Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
- Where
- Daqing, Nanchang, Tianjin
- Életkor
- 18 év and over
- People
- 670
- Run by
- Tianjin Medical University Second Hospital
See details and how to joinNCT07749924 - No phaseTaking peopleThe Supraspinal Control of Lower Urinary Tract Function in Patients With Orthotopic Sigmoid Neobladder.
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 40
- Run by
- Zhujiang Hospital
See details and how to joinNCT05558111 - 1/2. fázisTaking peopleRC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 55
- Run by
- Zhujiang Hospital
See details and how to joinNCT06341400 - 1/2. fázisTaking peopleSymbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Where
- Beijing, Nanjing, Ningbo, Tianjin
- Életkor
- 18 év and over
- People
- 132 worldwide
- Run by
- Pfizer
See details and how to joinNCT07421700 · EU 2025-523523-21-00